Rate My Professor Matthew Cheesman

Cheesman's research focuses on the pharmacology and biopharmaceutics of natural products, particularly their antimicrobial properties against antibiotic-resistant bacteria, including investigations into efflux pump inhibition, biofilm disruption, and synergy with conventional antibiotics. His work emphasizes Australian native plants such as Terminalia species, Syzygium, Hamamelis virginiana, and cyanobacterial compounds. Notable publications include 'A Review of the Antimicrobial Properties of Cyanobacterial Compounds' (Cock and Cheesman, 2023, cited 38 times), 'An assessment of the growth inhibition profiles of Hamamelis virginiana leaf extracts against a selection of pathogenic bacteria' (Cheesman et al., 2021, cited 29 times), 'Use of specific combinations of the triphala plant group as an alternative to antibiotics' (Tiwana et al., 2020, cited 68 times), 'Effects of Hamamelis virginiana L. Extracts on Pseudomonas aeruginosa Biofilms' (Cheesman et al., 2023), 'Plant Metabolites as Potential Agents That Potentiate or Block Bacterial Efflux Pumps' (Zai et al., 2025), 'Flavonoids Identified in Terminalia spp. Inhibit Gastrointestinal Pathogens' (Zai et al., 2025), 'Repurposing Non-Antibiotic Drugs as Novel Antibacterial Therapeutics' (Tiwana et al., 2025), and 'A Review of the Traditional Uses, Medicinal Properties and Pharmacology of Terminalia ferdinandiana' (Tiwana and Cheesman, 2021, cited 21 times). With more than 2,100 citations and an h-index of 13 on Google Scholar, his research impacts efforts to address antimicrobial resistance. He has served as guest editor for special issues on microbial infections and novel biological molecules and participates in funded research within the School of Pharmacy.